| 标题 |
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Désirée van der Heijde; James Cheng‐Chung Wei; Maxime Dougados; Philip J. Mease; Atul Deodhar; et al 出版日期:2018-10-22 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)